Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Identifieur interne : 002023 ( Main/Exploration ); précédent : 002022; suivant : 002024Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Auteurs : RBID : pubmed:20139819English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Artifacts, Female, Humans, Image Enhancement (methods), Male, Middle Aged, Neuroendocrine Tumors (diagnosis), Neuroendocrine Tumors (metabolism), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Octreotide (pharmacokinetics), Radiation Dosage, Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics), Receptors, Somatostatin (metabolism), Reproducibility of Results, Sensitivity and Specificity, Subtraction Technique, Systems Integration, Tomography, Emission-Computed, Single-Photon (methods), Tomography, X-Ray Computed (methods).
- MESH :
- chemical , analogs & derivatives : Octreotide.
- diagnosis : Neuroendocrine Tumors.
- chemical , diagnostic use : Octreotide, Radiopharmaceuticals.
- metabolism : Neuroendocrine Tumors, Receptors, Somatostatin.
- methods : Image Enhancement, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed.
- chemical , pharmacokinetics : Octreotide, Radiopharmaceuticals.
- Adult, Aged, Aged, 80 and over, Artifacts, Female, Humans, Male, Middle Aged, Radiation Dosage, Reproducibility of Results, Sensitivity and Specificity, Subtraction Technique, Systems Integration.
Abstract
Somatostatin receptor scintigraphy (SRS) is an established imaging modality for neuroendocrine tumors (NET). Additional single photon emission computed tomography (SPECT-CT) not only permits image fusion but also attenuation correction (AC) of SPECT data. This study evaluated whether attenuation corrected SPECT-images (SPECT[AC]) are more sensitive than nonattenuation corrected SPECT-reconstructions (SPECT[NAC]) for the detection of NET lesions.
DOI: 10.1097/RLU.0b013e3181becfcb
PubMed: 20139819
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?</title><author><name sortKey="Steffen, Ingo G" uniqKey="Steffen I">Ingo G Steffen</name><affiliation wicri:level="3"><nlm:affiliation>Klinik für Strahlenheilkunde, Charité Centrum 6 für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik für Strahlenheilkunde, Charité Centrum 6 für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Mehl, Sebastian" uniqKey="Mehl S">Sebastian Mehl</name></author><author><name sortKey="Heuck, Friederike" uniqKey="Heuck F">Friederike Heuck</name></author><author><name sortKey="Elgeti, Florian" uniqKey="Elgeti F">Florian Elgeti</name></author><author><name sortKey="Furth, Christian" uniqKey="Furth C">Christian Furth</name></author><author><name sortKey="Amthauer, Holger" uniqKey="Amthauer H">Holger Amthauer</name></author><author><name sortKey="Ruf, Juri" uniqKey="Ruf J">Juri Ruf</name></author></titleStmt><publicationStmt><date when="2009">2009</date><idno type="doi">10.1097/RLU.0b013e3181becfcb</idno><idno type="RBID">pubmed:20139819</idno><idno type="pmid">20139819</idno><idno type="wicri:Area/Main/Corpus">001A93</idno><idno type="wicri:Area/Main/Curation">001A93</idno><idno type="wicri:Area/Main/Exploration">002023</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Artifacts</term><term>Female</term><term>Humans</term><term>Image Enhancement (methods)</term><term>Male</term><term>Middle Aged</term><term>Neuroendocrine Tumors (diagnosis)</term><term>Neuroendocrine Tumors (metabolism)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Octreotide (pharmacokinetics)</term><term>Radiation Dosage</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Receptors, Somatostatin (metabolism)</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Subtraction Technique</term><term>Systems Integration</term><term>Tomography, Emission-Computed, Single-Photon (methods)</term><term>Tomography, X-Ray Computed (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neuroendocrine Tumors</term><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Image Enhancement</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Artifacts</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Radiation Dosage</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Subtraction Technique</term><term>Systems Integration</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Somatostatin receptor scintigraphy (SRS) is an established imaging modality for neuroendocrine tumors (NET). Additional single photon emission computed tomography (SPECT-CT) not only permits image fusion but also attenuation correction (AC) of SPECT data. This study evaluated whether attenuation corrected SPECT-images (SPECT[AC]) are more sensitive than nonattenuation corrected SPECT-reconstructions (SPECT[NAC]) for the detection of NET lesions.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20139819</PMID><DateCreated><Year>2010</Year><Month>02</Month><Day>08</Day></DateCreated><DateCompleted><Year>2010</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-0229</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical nuclear medicine</Title><ISOAbbreviation>Clin Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?</ArticleTitle><Pagination><MedlinePgn>869-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/RLU.0b013e3181becfcb</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Somatostatin receptor scintigraphy (SRS) is an established imaging modality for neuroendocrine tumors (NET). Additional single photon emission computed tomography (SPECT-CT) not only permits image fusion but also attenuation correction (AC) of SPECT data. This study evaluated whether attenuation corrected SPECT-images (SPECT[AC]) are more sensitive than nonattenuation corrected SPECT-reconstructions (SPECT[NAC]) for the detection of NET lesions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The imaging data (planar In-111-octreotide scintigraphy and SPECT-CT) of 50 consecutive patients (28 male; 22 female; age, 34-80; mean, 65 years) with NET were included in this retrospective analysis. SPECT data were reconstructed with and without integrated CT-based AC and then analyzed by 2 experienced readers for the presence of pathologic uptake in a blinded consensus reading. Fused SPECT-CT, contemporary CT/MRI, and clinical as well as imaging follow-up served as a reference standard. All foci were rated in both the SPECT(NAC)- and SPECT(AC)-reconstructions for intensity and contrast using a 6-point-score ("0 = no uptake/no delineation from surrounding tissue" to "5 = very high uptake/very strong delineation from surrounding tissue"). The scores were analyzed in a 6 x 6 contingency table using the McNemar Bowker test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 222 pathologic foci were detected by SPECT(NAC) and 227 foci by SPECT(AC), respectively. In 67 of 227 foci (29.5%), focus intensity/contrast increased after AC, whereas only 5 foci showed a decrease (P < 0.001). Sensitivity increased by 2.2% (P = 0.025; 95% CI: 0.02%-4.1%) as 5 foci were detected only by SPECT(AC). However, as these 3 patients were already diagnosed with systemic disease, there was no influence on the therapeutic strategy chosen.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Attenuation correction of somatostatin receptor scintigraphy-SPECT significantly improves focus visualization and, albeit slightly, also significantly increases sensitivity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steffen</LastName><ForeName>Ingo G</ForeName><Initials>IG</Initials><Affiliation>Klinik für Strahlenheilkunde, Charité Centrum 6 für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></Author><Author ValidYN="Y"><LastName>Mehl</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Heuck</LastName><ForeName>Friederike</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Elgeti</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Furth</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Amthauer</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ruf</LastName><ForeName>Juri</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Nucl Med</MedlineTA><NlmUniqueID>7611109</NlmUniqueID><ISSNLinking>0363-9762</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Artifacts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Image Enhancement</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName MajorTopicYN="Y">diagnosis</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiation Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Subtraction Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Systems Integration</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0b013e3181becfcb</ArticleId><ArticleId IdType="pii">00003072-200912000-00006</ArticleId><ArticleId IdType="pubmed">20139819</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002023 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002023 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20139819
|texte= Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20139819" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |